Лопатин Ю. М. Ингибитор ангиотензин-превращающего фермента зофеноприл в лечении больных инфарктом миокарда: обзор исследований проекта SMILE. Кардиоваскулярная терапия и профилактика. 2006;5(2):106-111.
1. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-77.
2. Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy. Lancet 1993; 342: 821-8.
3. Kober L, Torp-Pedersen C, Carlsen JE, et al. for the trandolapril cardiac evaluation (TRACE) study group: a clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 33: 1670-6.
4. Ambrosioni E, Borghi C, Magnani B. for the survival of myocardial infarction long term evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor on mortality on morbidity after anterior myocardial infarction. N Engl J Med 1995; 332: 80-5.
5. Fourth International Study of Infarct Survival Collaborative Group. ISIS-IV: a randomized factorial trial assessing early oral captopril. Oral mononitrate and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-85.
6. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6 week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-22.
7. Swedberg K, Held P, Kjekshus J, et al. Effects of early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992; 327: 678-84.
8. Ambrosioni E, Borghi C, Magnani B. Early treatment of acute myocardial infarction with angiotensin-converting enzyme inhibition: safety considerations. SMILE pilot study working party. Am J Cardiol 1991; 68: 101D-10.
9. Ambrosioni E, Borghi C, Magnani B. Survival of myocardial infarction long-term evaluation (SMILE) study: rationale, design, organization, and outcome definition. Control Clin Trials 1994; 15: 201-10.
10. Borghi C, Ambrosioni E on belhalf of the SMILE-2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: Results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J 2003; 145: 80-7.
11. Borghi C, Ambrosioni E. Effects of zofenopril on ischemia following myocardial infarction: the SMILE study. JACC 2004; 43: 263A.
12. Comparison between zofenopril and ramipril in combination with ASA on the extent of cardiovascular risk in patients with systolic left ventricular dysfunction after acute myocardial infarction (SMILE IV trial). http://www.menarini.com/clinical_trials.
13. Borghi C, Bacchelli S, Esposti D, et al, on behalf of the SMILE Study Investigators. Effects of the administration of an angiotensinconverting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. Am J Hypertens 1999; 12: 665-72.
14. Borghi C, Bacchelli S, Esposti DD, et al. Effects of the early ACEInhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction. Diabetic care 2003; 26: 1862-8.
15. Borghi C, Ambrosioni E. SMILE. In “Efficacy of myocardial infarction therapy”, Ed. By I.S.Nash& V.Fuster, Marcel Dekker Inc. NY-Basel 1999; 237-50.
16. Лопатин Ю.М. Дебаты по поводу совместного применения аспирина и ингибиторов ангиотензин-превращающего фермента: будет ли достигнут консенсус? Кардиология 2004; 6: 44-8.
